Semaglutide Side Effects: Nausea, Constipation, and When to Call Your Provider

Reviewed by Dr. Karron Power, MD; Board-Certified in Preventive Medicine and Anti-Aging and Regenerative Medicine, PowerMD, Greenbrae, CA

Published July 2026 | Medical content reviewed for accuracy

Starting semaglutide is a meaningful step. For most patients at PowerMD, the first weeks of treatment bring a welcome shift: food feels less consuming, portions feel naturally smaller, and the energy that goes into thinking about eating starts to ease. For many patients, those early weeks also bring something less welcome: nausea, stomach discomfort, or changes in bowel habits that can range from mildly inconvenient to genuinely distressing.

This guide is written to give you an honest, clinically grounded picture of what semaglutide does to the digestive system, why it causes the side effects it does, what you can do to manage them, and most importantly, which symptoms mean you should stop what you are doing and contact your provider right away. This is not a list of scary warnings designed to discourage use. It is the kind of information that helps patients stay on treatment, feel prepared rather than blindsided, and make good decisions when something does not feel right.

If you are considering semaglutide and want to understand the full picture before starting, or if you are already on treatment and wondering what you are experiencing is normal, this is the resource to read. And if you have questions that are specific to your situation, the team at PowerMD in Greenbrae is always available for physician-supervised guidance.

Common Side Effects: What the Clinical Data Actually Shows

The gastrointestinal side effects of semaglutide are well documented. In the STEP 1 through STEP 3 clinical trials that supported FDA approval of Wegovy for weight management, 43.9 percent of patients taking the 2.4 mg dose experienced nausea at some point during treatment, compared to 16.1 percent of patients on placebo. That number deserves context rather than alarm: the vast majority of patients who experienced nausea described it as mild to moderate, and only 4.3 percent of semaglutide patients discontinued treatment permanently due to gastrointestinal side effects.

The most common side effects reported across clinical trials and real-world use include:

• Nausea (the most frequent, affecting roughly 4 in 10 patients at some point)
• Constipation (often more persistent than nausea; median duration in STEP trials was 47 days)
• Diarrhea (typically shorter-lived; median duration approximately 3 days)
• Vomiting (less common than nausea; median duration approximately 2 days)
• Abdominal bloating or fullness
• Indigestion or reflux
• Belching and excess gas
• Reduced appetite beyond what is expected (which is usually the intended effect)
• Injection site redness, itching, or mild swelling

Less common but reported side effects include fatigue (reported in approximately 11 percent of Wegovy users in trials), headaches (often linked to dehydration or reduced caloric intake), and a modest increase in resting heart rate of approximately 2 to 4 beats per minute.

These are the effects that most patients experience to some degree, most commonly during the first four to eight weeks and particularly during dose escalation periods when the weekly dose increases from 0.25 mg to higher therapeutic levels.

Why Nausea Happens: The Gastric Emptying Mechanism

Understanding why semaglutide causes nausea makes the experience considerably easier to manage because it becomes predictable rather than mysterious.

Semaglutide works by mimicking GLP-1, a hormone the gut releases after eating to signal fullness to the brain and slow the movement of food out of the stomach. This gastric slowing is intentional: it extends the feeling of satiety and reduces overall caloric intake. The same mechanism also means that food stays in the stomach longer than it normally would. When the stomach is full or slowly emptying and the brain simultaneously receives appetite-suppression signals from the hypothalamus, the result is often nausea.

This is why nausea tends to be worst in the first several weeks of treatment and after each dose increase. The body is adjusting to a new rate of gastric emptying. For most patients, this adjustment takes two to four weeks at each dose level. The nausea does not last indefinitely; it typically peaks and then gradually resolves as the digestive system adapts.

According to a pooled GI tolerability analysis published in the journal Diabetes, Obesity and Metabolism, individual nausea episodes had a median duration of just eight days. Importantly, the same analysis found that less than one percentage point of the total weight loss achieved with semaglutide was attributable to nausea itself. The medication works through appetite regulation and metabolic changes, not by making patients too unwell to eat.

For clinical guidance on GLP-1 tolerability and patient management, the Cleveland Clinic’s GLP-1 agonist overview provides useful independent context for patients and providers.

Practical Ways to Reduce Nausea on Semaglutide

Most patients at PowerMD’s medical weight loss program find that a combination of dietary adjustments and injection timing changes significantly reduces nausea without requiring dose reduction or discontinuation.

Eat smaller portions more frequently. Large meals overwhelm a stomach that is already emptying slowly. Spreading intake into four to five smaller eating occasions across the day tends to be far more comfortable than two or three large meals.

Avoid high-fat and highly processed foods, especially around injection time. Fatty foods require more time to digest and worsen the slowed gastric emptying that semaglutide creates. In the first few days after each injection, patients typically tolerate lighter, lower-fat foods better.

Time your injection strategically. Many patients find that injecting on a day when they can eat lightly and rest helps. Some providers recommend evening injections so that any peak nausea occurs during sleep.

Stay hydrated, but sip rather than gulp. Large volumes of liquid in a slow-emptying stomach can worsen nausea. Small, frequent sips throughout the day maintain hydration without overwhelming the stomach.

Do not rush the dose escalation. The standard dose escalation schedule exists specifically to allow the gut to adjust before the dose increases. If nausea is significant, contact your provider about remaining at the current dose for an additional four weeks rather than escalating on schedule. This is a medically appropriate and common adjustment that is much better than discontinuing treatment entirely.

Ginger. Ginger-containing foods, teas, or supplements have a modest evidence base for nausea relief and are safe to use alongside semaglutide.

For patients with persistent moderate to severe nausea that does not respond to the above adjustments, physicians may consider short-term anti-nausea medication. A 2025 review in Mayo Clinic Proceedings noted that ondansetron (Zofran) is commonly prescribed for persistent GLP-1-related nausea, with domperidone as an alternative for appropriate patients.

Constipation Prevention: Why This Side Effect Is Different

Constipation is in some ways the more stubborn of the two main semaglutide GI side effects. While nausea typically improves as the body adapts to gastric slowing in the upper digestive tract, constipation reflects the same slowing mechanism affecting the entire gastrointestinal tract, including the colon. This is why the median duration of constipation in clinical trials (47 days) is substantially longer than that of nausea or diarrhea.

Patients who are not proactive about constipation management often find it worsens progressively rather than resolving on its own. The most effective approach is to begin prevention before significant constipation develops:

• Increase dietary fiber gradually. Vegetables, berries, legumes, and ground flaxseed all support bowel motility without causing the bloating that can accompany sudden large increases in fiber intake.
• Maintain hydration. Fiber without adequate water makes constipation worse. Aim for consistent fluid intake throughout the day.
• Move regularly. Even moderate walking stimulates bowel motility and helps counteract the slowing effect of the medication.
• Consider an osmotic laxative proactively. Polyethylene glycol (MiraLAX) is a gentle, non-habit-forming osmotic laxative that is safe for regular use and can be started as a preventive measure rather than waiting for severe constipation to develop.

Stimulant laxatives can provide temporary relief but are not the first choice for ongoing management. If constipation is severe, persistent, or accompanied by abdominal pain, contact your provider before self-treating. Severe or worsening constipation that does not respond to conservative management warrants clinical evaluation to rule out other contributing causes.

Red Flags: When to Call Your Provider (or Seek Emergency Care)

This section is the most important in the guide. The vast majority of semaglutide side effects are manageable with the adjustments described above. A small number of symptoms, however, require prompt medical attention because they may indicate rare but serious conditions that can develop in GLP-1 receptor agonist users.

Contact your provider promptly for:

• Constipation that does not respond to over-the-counter measures after two to three weeks
• Nausea that is severe, worsening rather than improving, or preventing adequate fluid intake
• Persistent vomiting that prevents keeping liquids down
• Signs of dehydration: dizziness, dark urine, rapid heartbeat, or confusion
• Changes in vision or eye pain
• Signs of low blood sugar if you are also using insulin or sulfonylurea medications: shakiness, sweating, confusion, or extreme hunger

Stop taking semaglutide and seek immediate medical care if you experience:

• Severe, persistent abdominal pain that radiates to the back, this may indicate pancreatitis, a rare but serious complication that requires emergency evaluation
• Yellowing of the skin or whites of the eyes (jaundice), fever, or severe upper right abdominal pain, these may indicate gallbladder disease, which occurs at a higher rate in semaglutide users than in the general population
• Difficulty breathing, severe rash, facial or throat swelling, these may indicate a serious allergic reaction
• A lump or swelling in the neck accompanied by hoarseness or difficulty swallowing, this requires immediate evaluation given the theoretical risk of thyroid C-cell tumors that led to the FDA’s boxed warning on this class of medication
• Black or bloody stools, these require urgent evaluation to rule out gastrointestinal bleeding
• Severe vomiting that does not stop, particularly if accompanied by fever or extreme abdominal pain

The World Health Organization’s guidance on GLP-1 obesity therapies notes that while GLP-1 receptor agonists have a strong safety profile at the population level, individual monitoring by a qualified healthcare provider is essential to identify and respond to adverse events early.

This is precisely why the physician-supervised model matters. At PowerMD, patients are monitored throughout their semaglutide program with scheduled follow-up appointments and access to Dr. Power’s clinical team when unexpected symptoms arise. Self-administered programs without ongoing provider access leave patients without the support structure needed to navigate the small but real subset of side effects that require professional guidance.

Why Supervised Care Changes the Semaglutide Experience

The difference between a supervised semaglutide program and an unsupervised one is not primarily about access to the medication. It is about what happens when something does not go as expected.

At PowerMD’s physician-supervised medical weight loss program, every patient begins with a complete health history review, baseline laboratory work, and a dosing protocol calibrated to their individual metabolic profile. When side effects occur, there is a physician to call. Dose adjustments, supportive prescriptions, and clinical judgment are immediately accessible. Patients do not have to guess whether what they are experiencing is expected or concerning.

For patients who have started semaglutide elsewhere and are experiencing side effects they are unsure how to manage, or who want to transition to physician-supervised care, PowerMD’s team in Greenbrae serves patients throughout Marin County, including Corte Madera, San Rafael, Mill Valley, Novato, Tiburon, and Fairfax.

You can also read our detailed Semaglutide Weight Loss Results Timeline to understand what to expect week by week throughout your program.

Call: (415) 785-7995 Book: Schedule Your Medical Weight Loss Consultation

Frequently Asked Questions

How long does semaglutide nausea last?

For most patients, nausea is most intense in the first two to four weeks of a new dose and tends to improve as the body adapts. A pooled analysis of the STEP clinical trials found a median individual nausea episode duration of just eight days. Nausea often returns to some degree with each dose increase, then settles again within a few weeks. The minority of patients (less than 5 percent in trials) experience persistent nausea requiring treatment adjustment or discontinuation.

Is constipation from semaglutide permanent?

No, but it is often one of the more persistent GI side effects, with a median duration of 47 days in clinical trial data. Proactive management with increased dietary fiber, adequate hydration, and a gentle osmotic laxative like MiraLAX significantly reduces its severity and duration. Constipation typically improves as the body adapts to the medication’s effect on gut motility, but this adaptation takes longer than for nausea.

Can I take anti-nausea medication with semaglutide?

Yes, in most cases. Over-the-counter options like ginger supplements are safe. For more significant nausea, your provider may prescribe ondansetron or another anti-nausea medication for short-term use during dose escalation periods. Always discuss with your prescribing provider before adding any new medication to your regimen.

What does pancreatitis from semaglutide feel like?

Pancreatitis presents as severe, persistent abdominal pain that often radiates to the back. It may be accompanied by nausea and vomiting, but unlike the typical nausea of early semaglutide use, pancreatitis pain is severe and does not improve with rest or dietary adjustment. If you experience sudden, severe abdominal pain at any point during semaglutide treatment, stop your injection and seek emergency medical care immediately.

Should I stop semaglutide if I feel sick?

Do not stop without speaking to your provider first if the symptoms are the common, manageable side effects described in this guide. Stopping prematurely is the most common reason patients do not achieve their weight loss goals. However, if you are experiencing severe symptoms, particularly severe abdominal pain, signs of dehydration from inability to keep liquids down, or any of the red flag symptoms described above, stop your injection and contact your provider or emergency services immediately.

Does nausea from semaglutide mean the medication is working?

Not specifically. The medication works primarily through appetite suppression and metabolic regulation, not through making you feel unwell. Clinical analysis showed that nausea accounts for less than one percentage point of total weight loss in STEP trial participants. Feeling nauseous does not mean the medication is more effective; managing side effects successfully while staying on treatment produces better long-term outcomes than pushing through discomfort without intervention.

This content is for educational purposes only and does not constitute medical advice. Side effects vary by individual, and any new or worsening symptoms should be discussed with your prescribing physician. If you experience a medical emergency, call 911 or go to your nearest emergency room.

PowerMD is located at 206 Bon Air Center, Greenbrae, CA 94904. Phone: (415) 785-7995. Serving patients throughout Marin County, the San Francisco Bay Area, and Northern California.